Overview

PoC in Rheumatoid Arthritis With Methotrexate

Status:
Completed

Trial end date:
2009-09-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to find out if 300 mg of BMS-582949 given once daily will be more effective than placebo after 12 weeks of treatment in subjects with rheumatoid arthritis who are also taking methotrexate

Phase:

Phase 2

Details

Lead Sponsor:

Bristol-Myers Squibb

Treatments:

Methotrexate